Pharma News

On February 6, AstraZeneca announced it has received a notification from Chinese authorities regarding $900,000 in unpaid import taxes related to two of its cancer medications.

Amgen announced the suspension of its weight loss drug AMG 133 (MarTide), a decision that has garnered significant attention.

U.S. Department of Justice announced that Pfizer's wholly-owned subsidiary Biohaven Pharmaceutical Holding Company has agreed to pay $59.74 million (approximately 434 million RMB) to resolve allegations related to false claims.

China announced that it has included the American PVH Group and Illumina, Inc. on its unreliable entity list.

The development of drugs targeting Claudin 18.2 (CLDN18.2) has gained momentum, heralding new hope in gastric cancer treatment.

Novo Nordisk officially released its annual report for 2024, revealing a remarkable revenue of 29.04 billion Danish kroner (approximately $42.13 billion), representing a 25% increase year-on-year.

Pfizer announced its financial results for the fourth quarter and the entire year of 2024, revealing a total revenue of $63.6 billion, a 7% increase year-on-year.

Novo Nordisk announced that the U.S. FDA has approved semaglutide for reducing the risk of kidney failure and disease progression in patients with chronic kidney disease (CKD) who also have diabetes.

Merck announced a suspension of its HPV cervical cancer vaccine supply to the Chinese market, a halt that will last at least until mid-2025.

On January 30, Roche announced its financial results for 2024, reporting total revenue of CHF 60.495 billion (approximately $66.4 billion with a conversion rate of 1 CHF = 1.0981 USD), representing a 7% year-on-year growth. However, net income declined to

On January 24, CR Pharmaceutical shocked the capital markets with its 2024 earnings forecast, predicting a staggering net loss attributable to shareholders of between 1.18 billion and 1.38 billion CNY.

On February 4, Merck & Co. announced its 2024 financial results, revealing total revenue of $64.168 billion, marking a 7% increase year-on-year. The pharmaceutical segment alone generated $57.400 billion, also reflecting a 7% growth.

On January 22, Johnson & Johnson announced its Q4 2024 financial results, revealing total annual revenue of $88.8 billion, representing a 4.3% increase year-on-year.

On January 10, 2025, Mediar Therapeutics announced a significant global licensing agreement with pharmaceutical giant Eli Lilly and Company to advance MTX-463 into a Phase II clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF).

On January 23, HengRui Pharma announced that the application for the marketing authorization of Shudi Insulin Injection (INS068) has been accepted by the National Medical Products Administration. This product marks the first self-developed long-acting ins

British Columbia's attorney general, Niki Sharma, announced that the B.C. Supreme Court has officially certified the province's class-action lawsuit against opioid manufacturers and distributors.

AbbVie and Neomorph have announced a strategic partnership and option-to-license agreement aimed at creating a new class of treatments using molecular glue degraders.

The Indian pharmaceutical industry is optimistic about expanding its footprint in the U.S. market under the new leadership of President Donald Trump. With only a limited number of medicine manufacturing plants in the U.S., India’s reliance on China for ph

Recently, WuXi AppTec announced at the JPM Conference that its robust operating cash flow, driven by business development and efficient operations, will be dedicated to advancing its global capacity and capabilities in CRDMO (Contract Research, Developmen